Evidence map›Paper›PMID 41010935›Full record

ArticleMedicina (Kaunas, Lithuania)2025

Impact of Adipokine Expression on Tumor Characteristics and Survival Outcomes in Patients with Renal Cell Carcinoma.

Oktay Halit Aktepe, Tugce Ulasli, Aytac Terzi, Fatma Gundogdu, Eda Caliskan Yildirim, Ahmet Melih Arslan, Huseyin Salih Semiz, Kemal Kosemehmetoglu, Aziz Karaoglu, Mustafa Erman and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicina (Kaunas, Lithuania), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Oktay Halit AktepeDepartment of Medical Oncology, Dokuz Eylul University, Izmir 35330, Turkey.ORCID 0000-0003-3540-0701
Tugce UlasliDepartment of Medical Oncology, Dokuz Eylul University, Izmir 35330, Turkey.
Aytac TerziDepartment of Medical Oncology, Dokuz Eylul University, Izmir 35330, Turkey.
Fatma GundogduDepartment of Pathology, Hacettepe University, Ankara 06230, Turkey.ORCID 0000-0001-7624-4034
Eda Caliskan YildirimDepartment of Medical Oncology, Sincan Research and Training Hospital, Ankara 06949, Turkey.ORCID 0000-0003-0785-0238
Ahmet Melih ArslanDepartment of Medical Oncology, Dokuz Eylul University, Izmir 35330, Turkey.
Huseyin Salih SemizDepartment of Medical Oncology, Dokuz Eylul University, Izmir 35330, Turkey.
Kemal KosemehmetogluDepartment of Pathology, Hacettepe University, Ankara 06230, Turkey.ORCID 0000-0002-7747-0460
Aziz KaraogluDepartment of Medical Oncology, Dokuz Eylul University, Izmir 35330, Turkey.
Mustafa ErmanDepartment of Medical Oncology, Hacettepe University Cancer Institute, Ankara 06230, Turkey.
Suayib YalcinDepartment of Medical Oncology, Hacettepe University Cancer Institute, Ankara 06230, Turkey.

Funding

Department of Scientific Research Projects Coordination Unit of Hacettepe University 18449
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdipokinesCarcinoma, Renal CellKidney NeoplasmsAdiponectinAdultAgedFemaleHumansImmunohistochemistryLeptinMaleMiddle AgedNephrectomyPrognosisProportional Hazards ModelsReceptors, LeptinAdipokinesAdiponectinLeptinReceptors, LeptinResistinadipokineadiponectinleptinrenal cell carcinomaresistin

Identifiers

PMID41010935
PMCPMC12472006

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.